Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Design Therapeutics, Inc. (DSGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/25/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/14/2023 8-K Quarterly results
Docs: "DESIGN THERAPEUTICS, INC. CONDENSED STATEMENTS OF OPERATIONS Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 17,064 $ 11,295 $ 32,794 $ 20,054 General and administrative 5,532 4,344 11,453 8,955 Total operating expenses 22,596 15,639 44,247 29,009 Loss from operations Other income, net 2,659 640 5,016 745 Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted-average shares of common stock outstanding, basic and diluted 55,948,990 55,670,780 55,928,625 55,589,510 DESIGN THERAPEUTICS, INC. CONDENSED BALANCE SHEETS June 30, December 31, 2023 2022 Assets Current assets: Cash, cash equivalents and investment securities $ 303,088 $ 330,387 Prepaid expense and other current assets 2,957 4,732 Total curren..."
06/01/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/09/2023 8-K Quarterly results
Docs: "DESIGN THERAPEUTICS, INC. CONDENSED BALANCE SHEETS March 31, December 31, 2023 2022 Assets Current assets: Cash, cash equivalents and investment securities $ 315,392 $ 330,387 Prepaid expense and other current assets 3,547 4,732 Total current assets 318,939 335,119 Property and equipment, net 1,905 1,947 Right-of-use asset, related party 3,447 3,612 Other assets 452 459 Total assets $ 324,743 $ 341,137 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 2,744 $ 3,025 Accrued expenses and other current liabilities 6,303 7,751 Total current liabilities 9,047 10,776 Operating lease liability, net, related party 2,878 3,051 Total liabilities 11,925 13,827 Total stockholders’ equity 312,818 327,310 Total liabilities and stockholders’ equity $ 324,743 $ 341,137 DESIGN TH..."
11/03/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
Docs: "DESIGN THERAPEUTICS, INC. CONDENSED STATEMENTS OF OPERATIONS Three Months Ended March 31, 2022 2021 Operating expenses: Research and development 8,759 3,875 General and administrative 4,611 1,805 Total operating expenses 13,370 5,680 Loss from operations Other income, net 105 166 Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average shares of common stock outstanding, basic and diluted 55,507,338 17,630,178 DESIGN THERAPEUTICS, INC. CONDENSED BALANCE SHEETS March 31, December 31, 2022 2021 Assets Current assets: Cash, cash equivalents and investment securities $ 371,220 $ 384,064 Prepaid expense and other current assets 2,651 1,371 Total current assets 373,871 385,435 Property and equipment, net 1,448 1,508 Right-of-use asset, related party 3,482 3,614 Total assets $ 37..."
03/22/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "FIRST AMENDMENT TO LEASE This First Amendment to Lease is entered into and effective as of March 18, 2022 by and between CROSSING HOLDINGS, LLC, a California limited liability company and DESIGN THERAPEUTICS, INC, a Delaware corporation , with reference to the recitals set forth below:"
03/10/2022 8-K Quarterly results
Docs: "Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results Phase 1 Trial of DT-216, a Novel FA GeneTACTM Molecule, in Patients with Friedreich Ataxia On Track to Begin Soon Preclinical Data Supporting Development of Novel GeneTACTM Small Molecules for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022 Well-Capitalized with $384.1 Million in Cash and Investments at the End of 2021 to Support Upcoming Milestones Carlsbad, Calif., March 10, 2022"
11/09/2021 8-K Quarterly results
Docs: "Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results Clinical Initiation of Lead GeneTACTM Program for Friedreich Ataxia On-track for the First Half of 2022 Carlsbad, CA, Nov. 9, 2021"
08/20/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/09/2021 8-K Quarterly results
08/06/2021 8-K Quarterly results
06/07/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
03/30/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy